Unknown

Dataset Information

0

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer.

ABSTRACT:

SUBMITTER: Ligumsky H 

PROVIDER: S-EPMC8700280 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Six-months immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: Updated results of the Vax-On study
| S-EPMC8660134 | biostudies-literature
Unknown Immunogenicity of a BNT162b2 vaccine booster in health-care workers.
| S-EPMC8504922 | biostudies-literature
Unknown Short term safety of booster immunization with BNT162b2 mRNA COVID-19 vaccine in healthcare workers
| S-EPMC8755369 | biostudies-literature
Unknown Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.
| S-EPMC8016402 | biostudies-literature
Unknown Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine.
| S-EPMC9258749 | biostudies-literature
Unknown Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1.
| S-EPMC8382485 | biostudies-literature
Unknown Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
| S-EPMC8519781 | biostudies-literature
Unknown Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose.
| S-EPMC9239876 | biostudies-literature
Unknown Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
| S-EPMC8276570 | biostudies-literature
Unknown Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection.
| S-EPMC8471735 | biostudies-literature